# Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors

> **NCT05235607** · PHASE1 · UNKNOWN · sponsor: **Sichuan University** · enrollment: 60 (estimated)

## Conditions studied

- Carcinoma
- Melanoma
- Bladder Cancer
- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** Tumor antigen-sensitized DC vaccine and their sensitized T cells subcutaneous administration

## Key facts

- **NCT ID:** NCT05235607
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-01
- **Primary completion:** 2023-06-01
- **Final completion:** 2023-12-02
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05235607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05235607, "Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05235607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*